GSK2879552

DRUG3 trials

Sponsors

GlaxoSmithKline

Conditions

Carcinoma, Small CellLeukaemia, Myelocytic, AcuteMyelodysplastic SyndromeMyelodysplastic Syndromes

Phase 1

Investigation of GSK2879552 in Subjects With Relapsed/Refractory Small Cell Lung Carcinoma

TerminatedNCT02034123

GlaxoSmithKlineCarcinoma, Small Cell

Start: 2014-02-04End: 2017-04-18Updated: 2019-12-06

A Phase I Dose Escalation Study of GSK2879552 in Subjects With Acute Myeloid Leukemia (AML)

TerminatedNCT02177812

GlaxoSmithKlineLeukaemia, Myelocytic, Acute

Start: 2014-08-27End: 2017-12-08Updated: 2019-06-28

Safety, Clinical Activity, Pharmacokinetics (PK) and Pharmacodynamics Study of GSK2879552, Alone or With Azacitidine, in Subjects With High Risk Myelodysplastic Syndromes (MDS)

TerminatedNCT02929498

GlaxoSmithKlineMyelodysplastic Syndrome, Myelodysplastic Syndromes

Start: 2017-07-31End: 2018-01-31Updated: 2019-05-14

Related Papers

Phase I, Open-Label, Dose-Escalation Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of GSK2879552 in Relapsed/Refractory SCLC.

2019-06-2862 citations